Litigation Details for Medicines Company v. Hospira Inc. (D. Del. 2009)

Medicines Company v. Hospira Inc. (D. Del. 2009)

Docket		Date Filed	2009-10-08
Court	District Court, D. Delaware	Date Terminated	2018-05-21
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	HOSPIRA INC.
Patents	7,582,727; 7,598,343
Attorneys	David A. Zwally
Firms	Phillips, McLaughlin & Hall, P.A.
Link to Docket	External link to docket

Details for Medicines Company v. Hospira Inc. (D. Del. 2009)

Date Filed	Document No.	Description	Snippet	Link To Document
2009-10-08				External link to document

The Medicines Company v. Hospira Inc. Litigation Summary, 1:09-cv-00750

Last updated: August 20, 2026

The Medicines Company v. Hospira Inc., No. 1:09-cv-00750, was a Hatch-Waxman patent dispute over generic bivalirudin for injection, the active pharmaceutical ingredient in Angiomax. The litigation centered on patents covering low-impurity bivalirudin batches and manufacturing methods. The dispute reached the Federal Circuit and generated important precedent on the on-sale bar for contract-manufactured pharmaceutical products.

The case ended through settlement and licensing. Hospira obtained a defined pathway to launch generic bivalirudin before expiration of the asserted patents, subject to the settlement terms.

What drug and patents were involved in The Medicines Company v. Hospira?

The case involved bivalirudin for injection, marketed by The Medicines Company as Angiomax for anticoagulation during percutaneous coronary intervention and related cardiovascular procedures.

Item	Details
Brand drug	Angiomax
Active ingredient	Bivalirudin
Plaintiff	The Medicines Company
Defendant	Hospira Inc.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:09-cv-00750
Filing date	2009
Regulatory pathway	Hospira ANDA for generic bivalirudin
Primary patent technology	Low-impurity bivalirudin batches and manufacturing processes
Principal patent	U.S. Patent No. 7,582,727
Related patent	U.S. Patent No. 7,598,343
Federal Circuit decisions	791 F.3d 1368 (Fed. Cir. 2015); 827 F.3d 1363 (Fed. Cir. 2016)

The asserted patents addressed a manufacturing problem associated with bivalirudin degradation. Bivalirudin can generate a problematic impurity during preparation. The claimed technology required pharmaceutical batches with impurity levels below specified thresholds, together with processes designed to produce those batches consistently.

What patents protected Angiomax against Hospira’s generic?

The main patent was U.S. Patent No. 7,582,727, titled "Pharmaceutical batches of bivalirudin with improved impurity profile." The patent claimed bivalirudin batches with low levels of a specified impurity, commonly identified in the litigation as an impurity generated by degradation of bivalirudin.

The related U.S. Patent No. 7,598,343 covered aspects of preparing bivalirudin pharmaceutical batches. The two patents formed a coordinated product and process estate:

Patent	General subject matter	Litigation significance
U.S. 7,582,727	Bivalirudin pharmaceutical batches with specified impurity limits	Core product and batch-quality patent
U.S. 7,598,343	Processes for preparing bivalirudin with improved impurity control	Manufacturing and process protection

The patents were important because a generic injectable product could potentially meet the active-ingredient requirement while still infringing claims directed to impurity content, batch composition, or the manufacturing process.

Why did The Medicines Company sue Hospira?

Hospira filed an abbreviated new drug application seeking FDA approval to market generic bivalirudin for injection. The filing included patent certifications challenging The Medicines Company’s listed patents.

The Medicines Company sued under the Hatch-Waxman framework. The filing of the patent challenge triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to court orders and other statutory events.

The complaint alleged that Hospira’s proposed generic product would infringe the asserted claims of the ’727 and ’343 patents. The dispute focused on:

1. Whether Hospira’s proposed bivalirudin batches met the claimed impurity limitations.
2. Whether Hospira’s manufacturing process infringed the asserted process claims.
3. Whether the patents were invalid because the claimed invention had been sold or offered for sale before the critical date.
4. Whether the asserted claims were anticipated or obvious.
5. Whether the contract manufacturing history involving Ben Venue Laboratories created an on-sale bar.

What was the central patent-validity issue?

The principal validity issue was the pre-AIA on-sale bar under 35 U.S.C. § 102(b). Hospira argued that the claimed bivalirudin batches had been commercially sold or offered for sale before the relevant patent filing date.

The Medicines Company had used Ben Venue Laboratories as a contract manufacturer to produce bivalirudin batches. Ben Venue manufactured batches under a commercial manufacturing arrangement, but The Medicines Company retained ownership of the drug product. The batches were not sold to an outside customer for commercial distribution.

The dispute required the courts to determine whether a contract manufacturing arrangement could qualify as a commercial sale or offer for sale of the patented product.

How did the district court rule?

The Delaware litigation proceeded through claim construction, infringement analysis, and validity proceedings. The district court found that Hospira’s proposed generic product and manufacturing activities infringed asserted claims and rejected Hospira’s principal invalidity arguments.

The court examined the manufacturing arrangements and the evidence concerning the bivalirudin batches produced by Ben Venue. The arrangement included payment for manufacturing services, but the product remained under The Medicines Company’s ownership and control.

The district court’s analysis treated the commercial manufacturing transaction as insufficient to create an on-sale bar because the transaction was a service arrangement rather than a commercial sale of the claimed product.

The court’s rulings created the basis for Hospira’s appeal to the Federal Circuit.

What did the Federal Circuit decide in 2015?

In The Medicines Company v. Hospira, Inc., 791 F.3d 1368 (Fed. Cir. 2015), the Federal Circuit addressed the patent claims and the district court’s infringement and validity analysis.

The Federal Circuit’s review focused on claim construction and the application of the asserted limitations to Hospira’s proposed product and manufacturing process. The decision did not eliminate the commercial significance of the asserted patents. The case returned to the district court for further proceedings concerning the remaining validity and infringement questions.

The 2015 decision was part of a broader series of Federal Circuit rulings involving the ’727 and ’343 patents. The appellate record addressed the interaction between:

• The impurity limits recited in the claims.
• The process used to manufacture bivalirudin.
• The evidentiary relationship between specific commercial batches and the patent claims.
• The pre-critical-date manufacturing activity.

What did the Federal Circuit decide in 2016?

The Federal Circuit issued a significant decision in The Medicines Company v. Hospira, Inc., 827 F.3d 1363 (Fed. Cir. 2016). The court held that the contract manufacturing arrangement did not constitute a sale or offer for sale of the claimed invention for purposes of the pre-AIA on-sale bar.

The Federal Circuit emphasized the commercial substance of the transaction. Ben Venue was paid to manufacture bivalirudin for The Medicines Company. The Medicines Company did not transfer title to the batches to Ben Venue, and the batches were not sold to a third-party customer.

The court distinguished:

• A commercial sale of the patented product, where title or possession is transferred for commercial purposes.
• A manufacturing-services agreement, where a contractor produces the product for the patent owner and is paid for services.

The decision limited the use of contract manufacturing activity as an on-sale-bar defense in pharmaceutical patent cases. It did not establish that all contract manufacturing arrangements are immune from the on-sale bar. The legal analysis depends on the terms and commercial substance of the specific transaction.

Why the 2016 decision mattered

The ruling reduced a major invalidity risk for pharmaceutical companies that use contract manufacturers before filing patents. It also confirmed that manufacturing batches for internal development, validation, or inventory purposes does not automatically amount to a commercial sale of the patented product.

For generic challengers, the decision made the on-sale defense more difficult where:

• The patent owner retained title to the product.
• The contractor only provided manufacturing services.
• The product was not delivered to an independent commercial customer.
• The transaction did not transfer commercial control of the claimed invention.

What was the litigation outcome?

The litigation was resolved through settlement rather than a final generic launch after complete appellate adjudication of every issue.

The settlement allowed Hospira to market generic bivalirudin under an agreed entry framework. Public reports identified a launch date in 2016, substantially before the nominal expiration of the principal patent estate. The agreement therefore converted the litigation from a binary injunction dispute into a negotiated early-entry license.

The settlement’s commercial effect was material:

• The Medicines Company preserved patent value through a controlled launch date.
• Hospira obtained a defined route to market.
• The FDA approval process could proceed subject to the settlement and applicable patent obligations.
• The parties avoided the cost and risk of continued appellate litigation.

Settlement terms in Hatch-Waxman cases can include launch licenses, manufacturing restrictions, supply terms, payment provisions, and allocation of future litigation risk. The complete economic terms of this settlement were not publicly disclosed in the judicial opinions.

When did Hospira’s generic bivalirudin enter the market?

Hospira obtained FDA approval for generic bivalirudin for injection and entered under the settlement framework in 2016. The publicly reported launch date was July 1, 2016, although settlement agreements can contain earlier-entry provisions tied to regulatory approval, court rulings, or third-party events.

The entry date preceded the nominal patent expiration date. That outcome indicates that the settlement operated as an authorized early-entry license rather than a complete defeat of The Medicines Company’s patent position.

What was the Orange Book status of the Angiomax patents?

The ’727 patent was listed in the FDA’s Orange Book for Angiomax and was the principal patent associated with the low-impurity bivalirudin formulation and batch technology.

Orange Book-listed patents can block or delay ANDA approval through the Hatch-Waxman framework when a generic applicant files a Paragraph IV certification and the innovator brings a timely infringement action. Process patents may have different regulatory effects from product or formulation patents, particularly where the generic applicant certifies that it will not market a product using the patented process.

The litigation demonstrates the commercial value of Orange Book-listed quality and manufacturing patents. The claims did not depend solely on a new chemical entity. They protected the pharmaceutical product’s impurity profile and the process used to achieve it.

Did the case involve a Paragraph IV challenge?

Yes. Hospira’s ANDA patent challenge created the Hatch-Waxman basis for the lawsuit. The case is therefore a Paragraph IV litigation involving an injectable generic drug.

The relevant litigation consequences included:

• A statutory stay of FDA approval after the infringement complaint.
• Discovery into Hospira’s proposed formulation and manufacturing process.
• Expert analysis of impurity content and batch characteristics.
• Examination of pre-critical-date manufacturing activity.
• Appellate review of the on-sale-bar issue.
• Settlement before the parties completed all possible merits proceedings.

A Paragraph IV certification does not itself invalidate a patent. It creates a pathway for the generic applicant to challenge the patent before commercial launch.

Was biosimilar risk relevant?

No. Bivalirudin is a synthetic small-molecule drug, not a biologic. The case involved an ANDA and the Hatch-Waxman framework, not a biosimilar application under the Biologics Price Competition and Innovation Act.

The relevant competitive threats were:

• ANDA-based generic entry.
• Patent expiry.
• Authorized or licensed generic supply.
• Additional generic applicants.
• Pricing pressure on injectable anticoagulants.

Biosimilar interchangeability, biologic reference-product exclusivity, and the BPCIA patent dance were not part of this dispute.

How strong was The Medicines Company’s patent estate?

The patent estate was commercially meaningful but technically narrow.

Strengths

The patents targeted a manufacturing attribute that could be difficult for a generic applicant to avoid. If the generic product necessarily met the claimed impurity limits, infringement could arise even where the generic manufacturer used a different commercial strategy.

The patents also created evidentiary leverage. The brand company could compare batch records, analytical specifications, impurity profiles, and manufacturing controls against the asserted claims.

The Federal Circuit’s 2016 ruling removed the contract-manufacturing on-sale defense that represented a major invalidity threat.

Limitations

The patents did not provide perpetual exclusivity for bivalirudin. Their value depended on:

• The enforceability of the specific claim limitations.
• The ability to prove that Hospira’s ANDA product met those limitations.
• The scope of any process claims.
• The absence of anticipation or obviousness defenses.
• The commercial timing of generic entry.

The settlement also demonstrated that the patents were not an absolute barrier to competition. They supported a negotiated entry date rather than a permanent exclusion.

What generic entry risks existed after settlement?

The principal risk was price erosion following Hospira’s launch. Injectable hospital products can face rapid formulary substitution when a generic receives FDA approval and the supplier has adequate manufacturing capacity.

The competitive risk depended on:

Risk factor	Effect
Hospira launch	Immediate direct generic price competition
Additional ANDA approvals	Greater discounting and share loss
Hospital purchasing contracts	Faster conversion from brand to generic
Supply reliability	Could limit or delay generic substitution
Patent enforcement	Could affect later entrants but not the licensed Hospira entry
Clinical differentiation	Limited if the generic matched the approved labeling

The settlement likely protected a period of branded sales before generic launch, but it did not preserve Angiomax’s pre-generic pricing structure after entry.

What litigation precedent came from the case?

The most durable legal precedent concerned the on-sale bar.

The Federal Circuit’s 2016 decision established that a commercial manufacturing agreement does not necessarily constitute a sale or offer for sale of the patented product. The court examined whether the transaction transferred the invention commercially, rather than treating any paid manufacturing activity as a statutory sale.

The case is frequently cited in patent-law analysis involving:

• Contract manufacturing.
• Pharmaceutical development batches.
• Pre-filing manufacturing activities.
• Ownership and title to drug product.
• Experimental and commercial use.
• On-sale-bar risk under pre-AIA § 102(b).

For pharmaceutical companies, the ruling supports a drafting and transaction strategy that clearly separates manufacturing services from product sales and documents ownership, control, confidentiality, and intended use of development batches.

Key Takeaways

• The Medicines Company sued Hospira in Delaware over an ANDA for generic bivalirudin for injection.
• The asserted patents, principally U.S. Patent Nos. 7,582,727 and 7,598,343, covered low-impurity bivalirudin batches and related manufacturing processes.
• The case generated Federal Circuit precedent on whether contract manufacturing creates an on-sale bar.
• The Federal Circuit held that the Ben Venue manufacturing arrangement was not a commercial sale of the claimed invention because The Medicines Company retained ownership and paid for manufacturing services.
• The dispute settled, allowing Hospira to launch generic bivalirudin in 2016 under an agreed early-entry framework.
• The case involved Hatch-Waxman and Paragraph IV issues, not biosimilar litigation.
• The patent estate was technically focused and commercially useful, but settlement converted exclusivity into a controlled early generic entry rather than a complete exclusion of Hospira.

FAQs

What was U.S. Patent No. 7,582,727 about?

It covered pharmaceutical batches of bivalirudin with an improved impurity profile, including specified limits for a degradation-related impurity.

Did Hospira invalidate the Angiomax patents?

No. The case did not end with a broad final judgment invalidating the asserted patents. The parties settled and Hospira entered under negotiated terms.

Did the Federal Circuit eliminate the pharmaceutical on-sale bar?

No. It held that the specific contract manufacturing arrangement in the case was not a commercial sale or offer for sale of the claimed invention.

Was Angiomax’s active ingredient protected by a composition-of-matter patent in this case?

No. The litigation focused on bivalirudin batch quality and manufacturing technology, not a basic composition-of-matter patent for bivalirudin.

What was the commercial significance of Hospira’s launch?

Hospira’s 2016 launch introduced approved generic bivalirudin competition before nominal patent expiry and created direct pricing and volume pressure on Angiomax.

References

1. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

2. The Medicines Company v. Hospira, Inc., 791 F.3d 1368 (Fed. Cir. 2015).

3. The Medicines Company v. Hospira, Inc., 827 F.3d 1363 (Fed. Cir. 2016).

4. U.S. Patent No. 7,582,727. (2009). Pharmaceutical batches of bivalirudin with improved impurity profile. United States Patent and Trademark Office.

5. U.S. Patent No. 7,598,343. (2009). Methods for preparing pharmaceutical batches of bivalirudin. United States Patent and Trademark Office.

6. 21 U.S.C. § 355. (2018). New drugs. United States Code.

7. 35 U.S.C. § 102(b) (pre-America Invents Act). (2011). Conditions for patentability; novelty. United States Code.